8EM Stock Overview
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Editas Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.83 |
| 52 Week High | US$10.68 |
| 52 Week Low | US$5.82 |
| Beta | 2.02 |
| 1 Month Change | -21.43% |
| 3 Month Change | -28.90% |
| 1 Year Change | -17.54% |
| 3 Year Change | -79.59% |
| 5 Year Change | -74.23% |
| Change since IPO | -72.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8EM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.8% | -1.0% | -1.2% |
| 1Y | -17.5% | -15.4% | 1.2% |
Return vs Industry: 8EM underperformed the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: 8EM underperformed the German Market which returned 1.2% over the past year.
Price Volatility
| 8EM volatility | |
|---|---|
| 8EM Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 8EM's share price has been volatile over the past 3 months.
Volatility Over Time: 8EM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 265 | Gilmore O’Neill | www.editasmedicine.com |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Editas Medicine, Inc. Fundamentals Summary
| 8EM fundamental statistics | |
|---|---|
| Market cap | €477.53m |
| Earnings (TTM) | -€144.01m |
| Revenue (TTM) | €73.43m |
6.5x
P/S Ratio-3.3x
P/E RatioIs 8EM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8EM income statement (TTM) | |
|---|---|
| Revenue | US$78.12m |
| Cost of Revenue | US$177.65m |
| Gross Profit | -US$99.53m |
| Other Expenses | US$53.69m |
| Earnings | -US$153.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | -127.40% |
| Net Profit Margin | -196.13% |
| Debt/Equity Ratio | 0% |
How did 8EM perform over the long term?
See historical performance and comparison